Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 34Active not recruiting 15Recruiting 13Terminated 12Unknown 6Not yet recruiting 3Withdrawn 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Renal Cell Carcinoma 1Adenocarcinoma of Lung 1

Interventions

Nivolumab 2pembrolizumab 1osimertinib 1icotinib 1famitinib 1dabrafenib 1cemiplimab 1alirocumab 1aldesleukin 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Pemetrexed 1Panitumumab 1Monatide (IMS 3015) 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Injections 1Immune Checkpoint Inhibitors 1Gefitinib 1Eflornithine 1Drug Therapy 1Cisplatin 1Celecoxib 1CTLA-4 Antigen 1Blood Specimen Collection 1Biopsy 1Biological Products 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Carcinoma, Non-Small-Cell Lung × Ipilimumab × Clear all
NCT04929041 2026-05-13

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

National Cancer Institute (NCI)

Phase 2/3 Suspended
427 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡